IBDEI11Y ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18554,1,4,0)
 ;;=4^MONOCYTIC LEUK CHR,RELAPSE
 ;;^UTILITY(U,$J,358.3,18554,1,5,0)
 ;;=5^206.12
 ;;^UTILITY(U,$J,358.3,18554,2)
 ;;=^336477
 ;;^UTILITY(U,$J,358.3,18555,0)
 ;;=206.11^^102^1191^32
 ;;^UTILITY(U,$J,358.3,18555,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18555,1,4,0)
 ;;=4^MONOCYTIC LEUK CHR,REMISSION
 ;;^UTILITY(U,$J,358.3,18555,1,5,0)
 ;;=5^206.11
 ;;^UTILITY(U,$J,358.3,18555,2)
 ;;=^267546
 ;;^UTILITY(U,$J,358.3,18556,0)
 ;;=206.22^^102^1191^33
 ;;^UTILITY(U,$J,358.3,18556,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18556,1,4,0)
 ;;=4^MONOCYTIC LEUK SUBAC,RELAPSE
 ;;^UTILITY(U,$J,358.3,18556,1,5,0)
 ;;=5^206.22
 ;;^UTILITY(U,$J,358.3,18556,2)
 ;;=^336478
 ;;^UTILITY(U,$J,358.3,18557,0)
 ;;=206.21^^102^1191^34
 ;;^UTILITY(U,$J,358.3,18557,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18557,1,4,0)
 ;;=4^MONOCYTIC LEUK SUBAC,REMISSION
 ;;^UTILITY(U,$J,358.3,18557,1,5,0)
 ;;=5^206.21
 ;;^UTILITY(U,$J,358.3,18557,2)
 ;;=^267548
 ;;^UTILITY(U,$J,358.3,18558,0)
 ;;=203.02^^102^1191^35
 ;;^UTILITY(U,$J,358.3,18558,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18558,1,4,0)
 ;;=4^MULT MYELOMA IN RELAPSE
 ;;^UTILITY(U,$J,358.3,18558,1,5,0)
 ;;=5^203.02
 ;;^UTILITY(U,$J,358.3,18558,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,18559,0)
 ;;=203.01^^102^1191^36
 ;;^UTILITY(U,$J,358.3,18559,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18559,1,4,0)
 ;;=4^MULT MYELOMA IN REMISSION
 ;;^UTILITY(U,$J,358.3,18559,1,5,0)
 ;;=5^203.01
 ;;^UTILITY(U,$J,358.3,18559,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,18560,0)
 ;;=202.18^^102^1191^37
 ;;^UTILITY(U,$J,358.3,18560,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18560,1,4,0)
 ;;=4^MYCOSIS FUNGOIDES MULT
 ;;^UTILITY(U,$J,358.3,18560,1,5,0)
 ;;=5^202.18
 ;;^UTILITY(U,$J,358.3,18560,2)
 ;;=^267455
 ;;^UTILITY(U,$J,358.3,18561,0)
 ;;=205.01^^102^1191^39
 ;;^UTILITY(U,$J,358.3,18561,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18561,1,4,0)
 ;;=4^MYELOID LEUK AC,REMISSION
 ;;^UTILITY(U,$J,358.3,18561,1,5,0)
 ;;=5^205.01
 ;;^UTILITY(U,$J,358.3,18561,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,18562,0)
 ;;=205.02^^102^1191^38
 ;;^UTILITY(U,$J,358.3,18562,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18562,1,4,0)
 ;;=4^MYELOID LEUK AC,RELAPSE
 ;;^UTILITY(U,$J,358.3,18562,1,5,0)
 ;;=5^205.02
 ;;^UTILITY(U,$J,358.3,18562,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,18563,0)
 ;;=205.11^^102^1191^27
 ;;^UTILITY(U,$J,358.3,18563,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18563,1,4,0)
 ;;=4^MEYLOID LEUK CHR,REMISSION
 ;;^UTILITY(U,$J,358.3,18563,1,5,0)
 ;;=5^205.11
 ;;^UTILITY(U,$J,358.3,18563,2)
 ;;=^267534
 ;;^UTILITY(U,$J,358.3,18564,0)
 ;;=205.12^^102^1191^40
 ;;^UTILITY(U,$J,358.3,18564,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18564,1,4,0)
 ;;=4^MYELOID LEUK CHR,RELAPSE
 ;;^UTILITY(U,$J,358.3,18564,1,5,0)
 ;;=5^205.12
 ;;^UTILITY(U,$J,358.3,18564,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,18565,0)
 ;;=205.22^^102^1191^41
 ;;^UTILITY(U,$J,358.3,18565,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18565,1,4,0)
 ;;=4^MYELOID LEUK SUBAC,RELAPSE
 ;;^UTILITY(U,$J,358.3,18565,1,5,0)
 ;;=5^205.22
 ;;^UTILITY(U,$J,358.3,18565,2)
 ;;=^336472
 ;;^UTILITY(U,$J,358.3,18566,0)
 ;;=205.21^^102^1191^42
 ;;^UTILITY(U,$J,358.3,18566,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18566,1,4,0)
 ;;=4^MYELOID LEUK SUBAC,REMISSION
 ;;^UTILITY(U,$J,358.3,18566,1,5,0)
 ;;=5^205.21
 ;;^UTILITY(U,$J,358.3,18566,2)
 ;;=^267536
 ;;^UTILITY(U,$J,358.3,18567,0)
 ;;=205.32^^102^1191^43
 ;;^UTILITY(U,$J,358.3,18567,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,18567,1,4,0)
 ;;=4^MYELOID SARCOMA IN RELAPSE
